Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Autopsy findings of post-COVID-19 vaccination deaths in Tokyo Metropolis, Japan, 2021

Hideto Suzuki a,*, Ayako Ro a, b, Aya Takada a, c, d, Kazuyuki Saito a, c, d, Kino Hayashi a

a Tokyo Medical Examiner’s Office, Tokyo Metropolitan Government, Tokyo, Japan
b Department of Legal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan
c Department of Forensic Medicine, Saitama Medical University, Saitama, Japan
d Department of Forensic Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan

ARTICLE INFO

Keywords:
COVID-19 vaccines
Death
Forensic autopsy

ABSTRACT

Background: COVID-19 vaccines have been used across Japan since 17 February 2021, and as of 17 April 2022, 1690 deaths potentially caused by vaccine-related adverse effects have been reported to the Ministry of Health, Labour and Welfare. However, the causal relationship between vaccination and death could not be fully evaluated because of a lack of sufficient information.

Methods: Autopsy cases in which deaths occurred within seven days after COVID-19 vaccination in Tokyo Metropolis and were handled by medical examiners were selected (n = 54). Age, sex, vaccine-related information, cause of death, and possible causal relationship between vaccination and death were examined.

Results: The mean age of the deceased individuals was 68.1 years, and the study sample consisted of 34 males (63.9%) and 20 females (37.0%). Thirty-seven and six individuals received Comirnaty and Spikevax, respectively (68.5% and 11.1% respectively). The manner of death included natural (n = 43), non-natural (n = 8), and undetermined (n = 3). The most frequent cause of death was ischemic heart disease (n = 16). Regarding causal relationships, 46 cases (85.2%) did not show a causal relationship to vaccination, except for myocarditis (n = 3), thrombosis-related death (n = 4), and others (n = 1).

Conclusion: Although many cases of deaths after COVID-19 vaccination in this study showed no definite causal relationship between the vaccination and deaths, some cases showed possible adverse events such as myocarditis. Autopsies are essential for detecting vaccine-related deaths, and the Japanese death investigation system needs to be reinforced from this viewpoint.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for coronavirus disease 2019 (COVID-19), has had a calamitous effect on the world [1,2]. The virus rapidly spread worldwide, leading to one of the most severe pandemics in human history. Vaccination is undoubtedly the most effective tool for preventing infectious disease, and is one of the most important breakthroughs in the history of medical science. The development of COVID-19 vaccines started in January 2020 with the identification of the genetic sequence of SARS-CoV-2 [3]. Vaccination against SARS-CoV-2 virus has proven to be a cornerstone of preventive strategies. The BNT162b2 (Comirnaty, BioNTech/Pfizer) and mRNA-1273 (Spikevax, Moderna) mRNA-based vaccines have demonstrated a high efficacy rate [4,5]. A recent study confirmed that three doses of BNT162b2 conferred high protection against hospital and emergency department admission due to both the delta and omicron variants in the first 3 months after vaccination [6]. A. Sheikh also showed that in comparison with the second vaccine doses, third or booster vaccine doses are associated with considerable added protection against symptomatic COVID-19 caused by the omicron variant [7].

On the other hand, COVID-19 vaccine-related adverse events, including anaphylaxis [8–11], myocarditis and pericarditis [12–18], and thrombosis with thrombocytopenia syndrome [19–20], have also been reported in the literature. Barda showed that the BNT162b2 was associated with an excess risk of myocarditis in their study in a nationwide mass vaccination setting, although the risk was substantially increased after SARS-CoV-2 infection [21]. Considering the scale of
vaccination programs both locally and internationally, some deaths may inevitably occur close to a COVID-19 vaccination, raising questions regarding the potential relationship between the death and the recent vaccination.

In Japan, the vaccines that have obtained pharmaceutical approval include BNT162b2, mRNA-1273, ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca), and NVX-CoV2373 (Novavaxid, Novavax). As of June 15, 2022, BNT162b2 and mRNA-1273 are the major vaccines that have been administered so far [22]. The vaccine was first administered to healthcare workers starting 17 February 2021, and subsequently offered to senior citizens and then to the general public aged 16 years and above. Those aged 12 years and above were eligible for vaccinations on 1 June 2021 (BNT162b2) and on 3 August 2021 (mRNA-1273). In addition, those aged 5–11 years became eligible for vaccinations on 21 January 2022 (BNT162b2). As of 15 June 2022, more than 103 million (81.9%) individuals in Japan have received at least the first dose of vaccine, and more than 76 million (60.7%) have received the third dose [23]. To monitor potential adverse effects of the vaccines, the Ministry of Health, Labour and Welfare (MHLW) has asked physicians/medical facilities to report suspected cases. The numbers of reported deaths that might be related to vaccine-related adverse effects were 1575 (Comirnaty), 149 (Spikevax), and one case (Vaxzevria) from 17 February 2021 to 15 May 2022 [24]. The council in MHLW discusses causal relationships between vaccination and reported cases and publishes the results. Although no cases have been judged as showing a definite causal relationship between vaccination and death so far, published data shows that causal relationship is unknown in a great majority of reported cases (1714 cases, 99.4%) because of the lack of sufficient information for evaluation of the relationship between vaccination and death [24].

Tokyo Metropolis is a metropolitan prefecture, and the medical examiner system has been implemented in the special wards of Tokyo Metropolis. All medicolegal deaths including natural, non-natural and undetermined manner of death occurred in the special wards of Tokyo Metropolis are reported to the Tokyo Medical Examiner’s Office. Medical examiners perform postmortem examinations to determine the manner and cause of death for these cases. Medical examiners also perform autopsies for deceased who died soon after COVID-19 vaccination to investigate if there is any evidence of causation between COVID-19 vaccination and deaths, except for cases showing severe purpuraform cases and cases showing evidence of a cause of death highly unlikely to be related to the vaccination, after reviewing the circumstances of death, the antemortem clinical course, and the postmortem radiographic findings. In this study, we investigated the autopsied cases of deaths occurring soon after COVID-19 vaccination to clarify the actual situation of COVID-19 vaccine-related deaths in Japan.

2. Materials and methods

From 1 April 2021 to 31 December 2021, forensic autopsies of 54 persons who received vaccination against COVID-19 within 7 days before death were performed at the Tokyo Medical Examiner’s Office. We collected the relevant documents (death certificates, autopsy reports, and reports of death scene investigations conducted by the police) of those cases, and examined age, sex, vaccine details, dose-related information (first or second dose), interval between vaccination and death, autopsy findings, and cause of death. Autopsy findings included macroscopic findings, histopathological findings, toxicological analysis and the results of blood biochemistry. Histopathological examination was performed in all cases, and blood ethanol levels were measured in all cases except for four cases (No. 5, 9, 27, 44). Toxicological analysis was performed in twenty cases (No. 3, 6, 7, 15, 17–20, 24, 32–34, 39, 40, 43, 45–47, 51, 53). Measurement of tryptase and/or Immunoglobulin E (IgE) was performed in fifteen cases (No. 12, 13, 17, 22, 23, 26, 30, 31, 35, 38, 47, 49, 51, 52, 54).

Among the autopsy findings, signs suggestive of anaphylaxis, thrombosis, myocarditis, and pericarditis were closely examined. In addition, we assessed possible causal relationships between vaccination and death. The Ethics Committee of the Tokyo Medical Examiner’s Office approved the study protocol and use of data (the approval number: 2020–3).

3. Results (see Table 1)

The mean age of the deceased individuals was 68.1 years (age range: 24–91 years), and the most frequent age group was 80–89 years (n = 14), followed by 70–79 years (n = 13), and 50–59 years (n = 11). The study sample consisted of 34 males (63.9%) and 20 females (37.0%). Thirty-seven and six individuals received Comirnaty and Spikevax, respectively (68.5% and 11.1% respectively), and information about the vaccine was not available in 11 cases. Twenty and 28 deaths were reported after the first and second doses, respectively (37.0% and 51.9% respectively), and information about the dose was not available in six cases. The interval between the last vaccination and death ranged from 40 min (case 17) to 7 days (case 9).

The manner of death was categorized as natural in 43 cases, non-natural in eight cases (cases 3, 6, 7, 13, 22, 24, 29, and 39), and undetermined in three cases (cases 32, 50, 53). Natural deaths included circulatory system diseases (n = 26), digestive system diseases (n = 5), endocrine, nutritional, and metabolic diseases (n = 4), neoplasms (n = 4), respiratory system diseases (n = 3), and other diseases (n = 1). Ischemic heart disease was the most frequent disease-related cause of death (n = 16), and postmortem investigations did not indicate a causal relationship to vaccination in 36 cases of natural death. Non-natural deaths included drowning (n = 6) and poisoning (n = 2). All cases of drowning happened in a bathtub during bathing, and postmortem investigations did not indicate a causal relationship to vaccination in cases of non-natural death. The three cases of death of undetermined manner showed no significant findings related to vaccination in two cases (cases 32, 50). In the third case (case 53), while the cause of death was not identified, slight lymphocyte and macrophage infiltration in the interstitial space of myocardium was observed. However, a causal relationship between death and vaccination was unknown.

In the assessment of adverse events, myocarditis was found to be the cause of death in two cases (cases 40, 54) (Fig. 1, Fig. 2.), and causal relationships to vaccination were possible. Another case showed myocarditis (case 4) while a competing cause of death (pre-existing ischemic heart disease) was found. A causal relationship to vaccination was possible, but could not be proven beyond doubt. Among the cases showing thrombosis, transverse sinus thrombosis (case 48), ischemic colitis secondary to superior mesenteric artery thrombosis (case 14), and pulmonary artery thromboembolism (case 8, 45) were found to be the causes of death. In cases 48 and 14, the anti-PF4 antibody level could not be measured because of difficulty in serum isolation. A causal relationship to vaccination was possible, but could not be proven beyond doubt. In case 8, chest discomfort was identified before vaccine administration, and organized thrombi were observed both in the pulmonary artery and deep vein of the left lower extremity. Organized thrombi were also found in the deep vein of the extremities in case 45.

Causal relationships were unlikely in these cases. None of the cases demonstrated signs suggestive of anaphylaxis, such as laryngeal edema and eosinophilic infiltration. Among fifteen cases in which serum tryptase and/or IgE was measured, elevated levels of tryptase was observed.
| No. | Age | Gender | Vaccine | Dose | Number of days post-vaccination | Cause of death | Autopsy findings relevant to cause of death | Other findings | Causal relationship |
|-----|-----|--------|---------|------|-------------------------------|----------------|-----------------------------------------------|---------------|-------------------|
| 1   | 72  | M      | Comirnaty | 1    | 3                             | Adhesion ileus | Adhesion of the small intestine and enlargement of the duodenum and the small intestine, post sigmoid colostomy | Diabetic ketoacidosis, cardiomegaly, severe coronary sclerosis, liver cirrhosis | No evidence |
| 2   | 86  | F      | Comirnaty | 1    | 6                             | Acute myocardial infarction | Cardiac tamponade due to a rupture of myocardial infarction in the posterior wall, severe coronary sclerosis with thrombus in the left circumflex branch, cardiomegaly | Cavernous hemangioma in the liver | No evidence |
| 3   | 86  | F      | Comirnaty | 1    | 1                             | Drowning        | Emphysema aquosum, watery gastric content | Hypertensive and diabetic nephroclerosis | No evidence |
| 4   | 91  | M      | Spikevax  | 1    | 6                             | Ischemic heart disease, myocarditis | Old myocardial infarction in the postlateral wall, severe coronary artery sclerosis, leukocyte and lymphocyte infiltration in the left anterior wall | Diabetic nephropathy, aortic sclerosis | Possible |
| 5   | 90  | M      | n.a.     | n.a. | 3                             | Ischemic heart disease | Cardiomegaly with old infarction of the antherosclerotic wall, severe coronary sclerosis, elevation of NT-pro BNP in blood (27400 pg/ml) | Aortic sclerosis, benign nephroclerosis | No evidence |
| 6   | 74  | F      | Comirnaty | 1    | 6                             | Drowning        | Emphysema aquosum, watery gastric content, pleural effusion | Coronary sclerosis, hypertensive and diabetic nephropathies, Old lung tuberculosis | No evidence |
| 7   | 87  | F      | Comirnaty | 1    | 1                             | Drowning        | Emphysema aquosum, watery gastric content, pleural effusion | Benign nephroclerosis | No evidence |
| 8   | 79  | M      | Comirnaty | 1    | 4                             | Pulmonary artery thromboembolism | Thromboembolism in the bilateral pulmonary trunk, deep vein thrombosis of the left lower extremity (containing organized thrombus) | Cardiomegaly, coronary sclerosis, unruptured abdominal aortic aneurysm, benign nephroclerosis | No evidence |
| 9   | 80  | M      | Comirnaty | 1    | 7                             | Volvulus of sigmoid colon | Panperitonitis due to a rupture of the volvulus of the sigmoid colon | Chronic subdural hematoma, Alzheimer’s disease | No evidence |
| 10  | 77  | F      | Comirnaty | 2    | 3                             | Incarceration of inguinal hernia | Strangulation ileus due to an incarceration of inguinal hernia, aspiration of vomitus | Chronic pyelonephritis, cardiomegaly, lacuna infarction | No evidence |
| 11  | 81  | M      | n.a.     | n.a. | 1                             | Ischemic heart disease | Severe coronary sclerosis, cardiomegaly with mild fibrotic scar, elevation of NT-pro BNP in blood (27400 pg/ml) | Aortic sclerosis | No evidence |
| 12  | 79  | F      | Comirnaty | 2    | 1                             | Ischemic heart disease | Severe sclerosis in the left anterior descending coronary artery | Mild amyloid disposition in the interstitial space of the cardiomycocytes | No evidence |
| 13  | 76  | M      | Comirnaty | 2    | 1                             | Drowning        | Emphysema aquosum, watery gastric content, pleural effusion | Unruptured thoracic aortic aneurysm, benign nephroclerosis, multiple renal cysts | No evidence |
| 14  | 78  | F      | Comirnaty | 1    | 6                             | Ischemic colitis  | Panperitonitis due to extensive necrosis of the small intestine, thrombus in the peripheral side of the superior mesenteric artery | Coronary sclerosis, aortic sclerosis, fatty liver | Possible |
| 15  | 82  | F      | Comirnaty | 2    | 1                             | Ischemic heart disease | Severe sclerosis with stent implantation in the right and left coronary arteries, multiple small fibrotic scars in the myocardium, elevation of NT-pro BNP in blood (9980 pg/ml) | Benign nephroclerosis, aortic sclerosis | No evidence |
| 16  | 77  | F      | Comirnaty | n.a. | 6                             | Malnutrition     | Body mass index 13.2, elevation of acetone in the blood (15.9 μg/ml) | Chronic hepatitis, hepatoma, aortic sclerosis | No evidence |
| 17  | 83  | F      | Comirnaty | 2    | 1                             | Aortic dissection | Rupture of aortic dissection, hemotherax, cystic medial necrosis in the aorta | Aortic sclerosis | No evidence |
| 18  | 67  | F      | Comirnaty | 2    | 5                             | Pyelonephritis   | Swelling of the right kidney, neutrophil infiltration in the tube and the interstitial space of the kidney | Cardiomegaly, coronary sclerosis, end-stage kidney disease | No evidence |
| 19  | 85  | M      | Comirnaty | n.a. | 6                             | Hemopneumothorax due to rupture of bulla | Hemotherax (right 350 ml, left 50 ml), multile bulla in the apex, emphysema | Coronary sclerosis, aortic sclerosis, benign nephroclerosis | No evidence |
| 20  | 79  | M      | Comirnaty | n.a. | 4                             | Gastric cancer   | | Pneumonia, old cerebral infarction, benign | No evidence |

(continued on next page)
**Table 1 (continued)**

| No. | Age | Gender | Vaccine | Dose | Number of days post-vaccination | Cause of death | Autopsy findings relevant to cause of death | Other findings | Causal relationship |
|-----|-----|--------|---------|------|---------------------------------|----------------|----------------------------------------------|---------------|-------------------|
| 21  | 77  | M      | Comirnaty | 1    | 1                               | Diabetic ketoacidosis | Carcinomatosis peritonitis due to gastric cancer in the cardia (sized 4 × 4 cm) | nephrosclerosis, aortic sclerosis | No evidence |
| 22  | 87  | F      | n.a.    | 1    | 2                               | Drowning           | Elevation of ketone in blood (3590 μmol/l), diabetic nephropathy | Cardiomegaly, old cerebral infarction | No evidence |
| 23  | 70  | F      | Comirnaty | 2    | 3                               | Sigmoid colon cancer | Sigmoid colon cancer (sized 4 × 3.2 cm), liver metastasis with extensive hemorrage and necrosis | Cardiomegaly, benign nephrosclerosis, fatty liver edema, pleural effusion | No evidence |
| 24  | 83  | F      | n.a.    | 2    | 2                               | Drowning           | Emphysema aquous, watery gastric content | Cardiomegaly, aortic sclerosis, benign nephrosclerosis | No evidence |
| 25  | 82  | M      | Comirnaty | 2    | 2                               | Lung cancer        | Hemorrhax (right 2100 ml) due to lung cancer (S6, sized 6 × 6 cm), multiple metastasis in the lung and liver | Cardiomegaly, benign nephrosclerosis | No evidence |
| 26  | 74  | F      | Comirnaty | 2    | 1                               | Heart failure due to mitral valve stenosis | Hypertrophy of the anterior mitral leaflet, cardiomegaly, elevation of NT-pro BNP in blood (6220 pg/ml) | Coronary sclerosis, old cerebral infarction | No evidence |
| 27  | 84  | F      | Comirnaty | 1    | 2                               | Acute myocardial infarction | Cardiac tamponade due to a rupture of myocardial infarction in the posterior wall | Aortic sclerosis | No evidence |
| 28  | 59  | M      | n.a.    | 1    | 6                               | Acute myocardial infarction | Cardiac tamponade due to a rupture of myocardial infarction in the lateral wall, severe coronary sclerosis, cardiomegaly | Aortic sclerosis | No evidence |
| 29  | 53  | F      | Comirnaty | 1    | 3                               | Alcohol intoxication | Blood ethanol level (3.5 mg/ml), urine ethanol level (3.89 mg/ml) | Liver cirrhosis | No evidence |
| 30  | 65  | M      | Comirnaty | n.a. | 0                               | Ischemic heart disease | Old myocardial infarction in the anterior and lateral wall, severe sclerosis in the left coronary artery, cardiomegaly | Fatty liver, aortic sclerosis | No evidence |
| 31  | 66  | M      | Comirnaty | 2    | 3                               | Ischemic heart disease | Old myocardial infarction in the anteroseptal wall, severe coronary sclerosis | Lung edema, tonsillar hypertrophy | No evidence |
| 32  | 69  | M      | n.a.    | n.a. | 1                               | Unknown            | – | Severe postmortem change of the whole organ, malnutrition, emphysema, coronary sclerosis | No evidence |
| 33  | 55  | M      | Comirnaty | 2    | 0                               | Bacterial pneumonia | Significant neutrophil infiltration and bacteria in the alveoli of bilateral lungs, aspiration of vomitus, myotonic dystrophy | Coronary sclerosis | No evidence |
| 34  | 51  | M      | Comirnaty | 2    | 2                               | Bacterial pneumonia | Lobar pneumonia in the middle lobe of the right lung, elevation of CRP in blood (28.03 mg/dl) | Liver cirrhosis, malnutrition | No evidence |
| 35  | 40  | M      | Spikevax | 2    | 3                               | Ischemic heart disease | Severe coronary sclerosis | Fatty liver | No evidence |
| 36  | 65  | M      | n.a.    | 2    | 2                               | Gastric cancer      | Gastric cancer (sized 12 × 10 cm), metastasis in multiple organs (heart, adrenal gland, bone marrow) | Old myocardial infarction, coronary sclerosis | No evidence |
| 37  | 74  | M      | Comirnaty | 2    | 1                               | Ischemic heart disease | Severe coronary sclerosis, lung edema and congestion | Old renal infarction | No evidence |
| 38  | 88  | F      | Comirnaty | 2    | 2                               | Strangulation ileus | Incarceration of hernia (greater omentum), necrosis of the jejunum, secondary pneumonia | Senile amyloidosis, aortic sclerosis, benign nephrosclerosis, old lung tuberculosis | No evidence |
| 39  | 55  | M      | Comirnaty | 1    | 2                               | Poisoning (methamphetamine and antipsychotics) | Methamphetamine (2.69 μg/ml), bromazepam (0.58 μg/ml) and myanerin hydrochloride (0.14 μg/ml) in blood | Fatty liver | No evidence |
| 40  | 24  | M      | Spikevax | 2    | 3                               | Myocarditis         | Scattered necrosis and fibrosis of cardiomyocytes with a perivascular pattern of inflammatory cell infiltration (consisting of predominantly lymphocytes) | – | Possible |
| 41  | 53  | M      | Comirnaty | 1    | 0                               | Ischemic heart disease | Severe coronary sclerosis, myocardial infarction in the anteroseptal wall | Fatty liver | No evidence |
| 42  | 59  | M      | n.a.    | 2    | 6                               | Diabetic ketoacidosis | Elevation of ketone in blood (13000 μmol/l), dehydration, diabetic nephropathy, fibrosis of the pancreas | Old myocardial infarction, coronary sclerosis | No evidence |
| 43  | 47  | M      | Comirnaty | 1    | 5                               | Ischemic heart disease | Severe coronary sclerosis, contraction band in cardiomyocytes | Fatty liver | No evidence |
in case 13 (411 μg/L) and case 47 (36.4 μg/L), however, these cases did not show clinical manifestations or histopathological findings suggestive of anaphylaxis.

4. Discussion

There are many autopsy case reports of death suspected of severe adverse effects of COVID-19 vaccine [15–17,25–33], however, few studies investigate autopsy findings and cause of death of a series of death following vaccination with COVID-19 vaccines. Edler reported four death cases after vaccination with Comirnaty. They concluded that a causal relationship between vaccination and death was not established, because three deceased died in the context of pre-existing conditions (severe cardiovascular diseases) and one developed COVID-19 pneumonia as cause of death [34]. Schneider investigated causes of death of eighteen cases died after COVID-19 vaccine, and found one case of myocarditis and two cases of vaccine-induced immune thrombotic thrombocytopenia (VITT) among eighteen cases, whereas the cause of death was attributed to preexisting disease in the remaining fifteen cases [35]. Yeo investigated 33 deaths that occurred within 72 h after COVID-19 vaccination in Singapore, and found no definite causal relationship between the vaccination and deaths [36]. They also showed that circulatory system diseases (e.g., ischemic heart disease) were the most frequent cause of death. In this study, a majority of cases (85.2%, 46 out of 54 cases) did not show a causal relationship between vaccination and death. In addition, two cases of death from pulmonary artery thromboembolism may have occurred irrespective of vaccination. Previous studies and our results suggest that the proportion of death by severe adverse events of vaccines is minority in a series of forensic autopsy cases of death following vaccination with COVID-19 vaccines. Due to the large numbers of people being vaccinated, some people may coincidentally experience medical events (e.g., heart attacks) in the days or weeks after vaccination that may not be related to the vaccination, and such deaths are to be expected inevitably.

On the other hand, myocarditis was listed as a cause of death in two cases and as a competing cause of death in one case. In addition, slight lymphocyte and macrophage infiltration was observed in the internal space of cardiac muscle in one case, although the cause of death was unknown. Most cases of myocarditis in vaccine recipients occur in young males, particularly following the second dose [14]. These features are compatible with those observed in cases in this study (cases 40, 54). The reasons for the higher incidence among males are unclear, but may be due to different effects of sex hormones on the cell-mediated immune response, with testosterone promoting a more pronounced Th1 stimulation and estrogen displaying inhibitory effects on pro-inflammatory T cell responses [18]. The histopathological characteristics of vaccine-associated myocarditis following COVID-19 vaccination have been reported to vary among cases [14–17]. Some of these cases describe areas of acute inflammation with myocyte necrosis and predominantly lymphocytic infiltration [14], whereas others describe diffuse or scattered foci of contraction band necrosis with hypercontracted sarcosomes and predominantly neutrophil and histiocyte infiltrates suggesting

| No. | Age | Gender | Vaccine | Dose | Number of days post-vaccination | Cause of death | Autopsy findings relevant to cause of death | Other findings | Causal relationship |
|-----|-----|--------|---------|------|-------------------------------|----------------|---------------------------------------------|---------------|-------------------|
| 44  | 84  | M      | n.a.    | 2    | 5                             | Cor pulmonare due to emphysema | Hypertrophy of the right ventricle, emphysema, elevation of NT-pro BNP in blood (57900 pg/ml) | Bronchitis, coronary sclerosis, old cerebral hemorrhage | No evidence |
| 45  | 49  | M      | n.a.    | 2    | 5                             | Pulmonary artery thromboembolism | Thromboembolism in the bilateral pulmonary trunk, deep vein thrombosis of bilateral lower extremities (containing organized thrombus) | Fatty liver | Unlikely |
| 46  | 67  | F      | Comirnaty | 2    | 0                             | Ischemic heart disease | Severe coronary sclerosis, lung edema | Benign nephrosclerosis, aortic sclerosis | No evidence |
| 47  | 56  | M      | Spikevax | 2    | 2                             | Ischemic heart disease | Cardiomegaly with multiple fibrotic scars, severe coronary sclerosis, lung edema and congestion | Benign nephrosclerosis, fatty liver | No evidence |
| 48  | 52  | M      | n.a.    | 1    | 1                             | Cerebral hemorrhage | Transverse sinus thrombosis, massive cerebral hemorrhage (sized 10 × 10 cm) with ischemic lesion | Gastromalacia | Possible |
| 49  | 48  | F      | Spikevax | 1    | 3                             | Diabetic ketoacidosis | Elevation of ketone (9820 μmol/l) and HbA1c (10.3%) in blood, dehydration, | – | No evidence |
| 50  | 39  | M      | Comirnaty | 2    | 3                             | Unknown | – | Lung edema, a slight lymphocyte and macrophage infiltration in the internal space of cardiac muscle | Unknown |
| 51  | 52  | M      | Comirnaty | 2    | 3                             | Ischemic heart disease | Severe coronary sclerosis, cardiomegaly, lung edema | Benign nephrosclerosis, fatty liver | No evidence |
| 52  | 56  | M      | Comirnaty | 2    | 2                             | Subarachnoid hemorrhage | Dissection of the left vertebral artery | Lung edema, cardiomegaly | No evidence |
| 53  | 49  | M      | Comirnaty | 2    | 0                             | Unknown | – | Hypoxic encephalopathy, severe coronary sclerosis, cardiomegaly, liver cirrhosis, pneumonia | No evidence |
| 54  | 39  | M      | Spikevax | 2    | 3                             | Myocarditis | Scattered inflammatory cell infiltration (consisting of predominantly monocytes) in the interstitial space of cardiomyocytes/around the coronary arteries, interstitial edema, eosinophilic and wavy change of cardiomyocytes | Lung edema, coronary sclerosis | Possible |

n.a.; not available.
cerebral venous thrombosis and splanchnic venous systems. However, a distinctive feature of VITT is thrombosis in unusual locations, including cerebral venous thrombosis and splanchnic venous thrombosis [35,38]. Based on the autopsy data, the recurrent findings were intracranial hemorrhage and diffused microthrombi located in multiple areas [29]. Cases have been reported to be typically identified between 4 and 30 days after vaccination with vector vaccines Vaxzevria and Janssen [39]. Similar complications can occur following mRNA-based vaccines, although their incidence rate has been estimated to be lower [40]. From these findings, the causal relationship was considered to be possible in case 48 in this study, although anti-PF4 antibody could not be measured. Regarding thrombosis related complications, immobilization due to common symptoms after vaccination, such as fatigue, fever and muscle/joint pain might be indirectly concerned with a formation of thrombus, in addition to the immunological mechanism mentioned above, however, this involvement is not directly proven by autopsies.

The Japanese death investigation system is still in a developmental stage, and the autopsy rate for medicolegal deaths is only 11.5% (2019) [41]. The police mainly determine whether forensic autopsy should be performed from the criminal standpoint, especially in areas without a medical examiner system [42]. The fundamental law of promoting inquiry of cause of death was established in June 2019 in Japan [40]. This law emphasizes the role of death investigation for improvement of public health, but it is questionable whether this concept has fully infiltrated into Japanese society. Pathological autopsy is another autopsy to investigate cause of death in Japan, especially when patients die suddenly in the hospitals. However, it needs consent of the relatives and the deceased after COVID-19 vaccination has been rarely performed pathological autopsy [43]. As mentioned above, a causal relationship was not fully evaluated in a great majority of cases of deaths occurring after COVID-19 vaccination in Japan because of the lack of sufficient information, suggesting that such cases have rarely undergone autopsy. Therefore, the Japanese death investigation system needs to be reinforced to adequately evaluate causal relationships between death and vaccination.

This study had several limitations. First, the sample size was not large, and all of the data were collected from an area inhabited by approximately 7% of the total Japanese population. Therefore, the results may not be generalizable to the entire Japanese population. Further large-scale studies are needed in the future to address this limitation. Second, blood biochemical test and toxicological analysis were not necessarily performed in this study sample, especially in cases in which causes of death were evident from macroscopic and histopathological findings. The anti-PF4 antibody level was not measured in this study. Five deaths were caused by ischemic heart disease with thrombus in coronary arteries with severe atherosclerotic changes. We considered the severe atherosclerotic changes to be a significant factor of thrombi, but the possibility of VITT may have been underestimated in these cases. Third, regarding number of day post vaccination, we selected persons who received vaccination against COVID-19 within 7 days, because the average of time intervals between vaccine administration and the first symptoms was 7.8 days in the previous study [3], however, further studies including persons who died 14 days or longer after vaccination may clarify delayed presentation of severe adverse effects of vaccination. Fourth, we mainly examined previously known severe adverse effects (e.g., myocarditis) to assess possible causal relationships between vaccination and death, however, we cannot possibly deny that rare complications or complications difficult to be proven by autopsies, such as seizures [44], might be concerned with non-natural death (e.g., drowning during bathing).

In conclusion, although many cases of deaths occurring soon after COVID-19 vaccination in this study showed no definite causal relationship between the vaccination and the death, a few cases showed possible adverse events, such as myocarditis. Autopsies are essential for detecting vaccine-related deaths, but in Japan, many such deceased individuals may not have undergone autopsies, thereby precluding the collection of adequate information to determine a causal relationship between death and vaccination. The Japanese death investigation system needs to be reinforced from this viewpoint.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
